Background: Inflammatory bowel disease (IBD) needs early interventions and an individual specialist-patient relationship. Distance from a tertiary IBD center might affect patient's disease course and outcome. We investigated whether the patient-to-specialist distance has an impact on the disease course using the well-defined patient collective of the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Methods: Patient's home address at diagnosis (postal zip code) was extracted from the SIBDCS database. Distance between each zip code and the nearest located IBD specialist center was calculated and classified into the following three sections based on proximity: <10 km (group 1); 10-35 km (group 2); >35 km (group 3). Results: Our study included in total 408 IBD patients [234 Crohn's disease (CD), 154 ulcerative colitis (UC), 20 IBD unclassified (IBDU)]. Median age was lowest in group 2 at diagnosis (G1: 28 years; G2: 21 years, G3: 26 years, p < 0.01). The diagnostic delay did not differ between groups. CD patients in group 1 were treated more often with anti-tumor necrosis factor (TNF) agents (72% versus 56%, p = 0.04) and 5-aminosalicylates (44% versus 28%, p = 0.04) than in group 3. UC/IBDU patients in group 1 were treated more often with corticosteroids than patients in group 3 (83% versus 58%, p < 0.01). The occurrence of IBD-related surgeries did not differ between groups. Conclusions: Patient-to-specialist distance might affect drug treatment. However, disease course and the need for IBD-related surgery does not seem to be associated with a longer distance to specialist care in Switzerland.
Introduction
The incidence of inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), is increasing worldwide in adults as well as in pediatric patients. [1] [2] [3] Patients are exposed to a tremendous social and personal burden, 4 due to an often chronic-relapsing disease course and associated complications, such as fistulas, abscesses, or stenoses. [5] [6] [7] Shortening the delay between symptom onset and diagnosis (referred to as 'diagnostic delay') is key to avoiding long-term complications, hospitalization, and surgery. 8 In addition, optimized therapy through a tight and individual physician-patient relationship is necessary. Due to the increasing number of therapeutic options, 9,10 a personalized therapeutic Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study approach often requires specialist knowledge from tertiary care centers. Barriers like the distance to such a specialist may prevent effective access to personalized IBD care.
The travel distance to tertiary care centers is relevant for health and disease outcome. 11 Especially in oncologic diseases, increasing travel requirements results in worse disease outcome and inappropriate treatment strategies. 12 In IBD, the distance between the patient's home and specialists could therefore influence the risk of delayed diagnosis and the rate of clinical complications by hindering close and specialized therapy monitoring. A recent study from the United States (US) showed an increased need for surgery in IBD patients living at longer distances to an IBD center, 13 but did not analyze whether the distance has an impact on the diagnostic delay.
We aimed to investigate whether the distance of the IBD patient to the closest IBD specialist tertiary care center (patient-to-specialist distance; PTSD) is associated with diagnostic delay and disease outcome parameters in a Swiss IBD patient population. We hypothesized that an increase in distance might have an adverse impact on diagnostic delay, treatment, and disease-related complications.
Patients and methods

Study population
Our data was retrieved from the database of the SIBDCS, which has collected data from patients with CD, UC, and IBD unclassified (IBDU) from all over Switzerland since November 2006. Upon consent, pediatric and adult IBD patients are enrolled by their gastroenterologists, either in hospitals or in private practices, by using specific questionnaires for enrollment and for a yearly follow up, thus providing epidemiological, clinical, and psychosocial data, as well as information about health resource consumption. 14 In our study, both pediatric and adult patients were included. Tertiary care centers, basically being equivalent to university hospitals, were considered 'specialized centers' (Figure 1 ). When calculating PTSD, we used the home address at time of diagnosis as a reference. Enrollment into the cohort occurred not only at time of diagnosis, but also at later time points, depending on when the treating physician enrolled the patient. To avoid unpredictable effects on PTSD, and study results from patients moving to another area between the diagnosis of IBD and enrollment into the cohort, we excluded all SIBDCS patients with enrollment into the cohort later than 6 months after 
Ethical considerations
The SIBDCS has been approved by the Ethics Committee of the Canton of Zurich (EK-1316). All patients signed informed consent, and the current substudy has been evaluated and approved by the scientific board of the SIBDCS. Tables 1-3 . Based on the defined distance groups, median patient proximity to specialist was 3.6 km (group 1, IQR 1.9-5.8 km), 20.8 km (group 2, IQR 15.4-27.6 km), and 45.8 km (group 3, IQR 40.5-49.2 km). Group 1 (62%) contained more male patients than group 2 (48%) or group 3 (51%) (p = 0.03). Median disease duration was longer in group 1 (6 years), than in group 2 and 3 (both 4 years) (p < 0.01). Median age at diagnosis was lowest in group 2 (21 years) than in group 1 (28 years) and 3 (26 years) (p < 0.01). There were no differences in IBD-types between groups.
Results
Study population
The detailed clinical characteristics of CD patients according to PTSD are listed in Table 2 .
Differences were found in the following characteristics: patients in group 1 had a longer median disease duration (7 years, IQR 3-9 years), than patients in groups 2 and 3 (both 4 years, both p < 0.01). Median age at diagnosis was lowest in group 2 (19 years) than in groups 1 (28 years) and 3 (27 years) (p < 0.01). Patients in group 3 had the shortest diagnostic delay (median 2 months, IQR: 2-14 months), while the diagnostic delay was longer in group 1 (5 months, IQR: 2-22 months) and group 2 (7 months, IQR: 3-14 months) (P1 versus 3 = 0.05).
The disease behavior differed between groups (p = 0.01, P1 versus 3 = 0.01): patients in group 1 had more often a stricturing behavior (B2 + B2p, 27.3%) than a nonstricturing and nonpenetrating Detailed clinical characteristics of UC and IBDU patients according to PTSD are shown in Table 3 . Differences were found in the following characteristics: group 1 (72%) contained more male patients than group 2 (53%) or group 3 (45%) (p = 0.01). Median disease duration was longer in group 1 (5 years), than in group 2 (4 years) and group 3 (3 years) (p = 0.02). Disease location at diagnosis differed between groups (p < 0.01): patients in group 2 more often had left-sided colitis (43.1%), while group 3 more often had proctitis (31.6%). At the last follow up, disease localization no longer differed between groups.
Treatment of CD patients
Detailed treatment information is summarized in Table 2 . At the time of enrollment, patients in group 1 (25%) were treated more often with 5-aminosalicylates (5-ASA) than patients in group 2 (8%) and group 3 (11%) (p < 0.01). There was no difference for the use of anti-TNF agents, steroids, antibiotics, calcineurin inhibitors, immunomodulators, and other biologicals between groups.
At the time of last follow up, anti-TNF agents were used more often in group 1 (51.5%) than in group 2 (43.3%) and group 3 (33.3%, p = 0.09, P1 versus 3 = 0.03). There was no difference in the use of 5-ASA, steroids, antibiotics, calcineurin inhibitors, immunomodulators, and other biologicals between groups at follow up.
Analyzing the drug treatment at any time during the entire study period, 71.7% of patients in group 1 were treated with anti-TNF agents compared with 61.7% in group 2 and 55.6% in group 3 (P1 versus 3 = 0.04). In addition, during the entire study period CD patients of group 1 had a higher use of 5-ASA (44.4%) than patients of group 2 (29.6%) and group 3 (27.8%) (p = 0.04).
Intestinal resection, fistula, and abscess surgery were not different between groups.
Treatment of UC/IBDU patients
Detailed treatment information is summarized in Table 3 . At the time of enrollment, UC and IBDU patients in group 1 (40.6%) and in group 2 (38.9%) were more often treated with steroids than in group 3 (15.8%) (p = 0.02). Especially, systemic steroids were used more often at enrollment in group 1 (34%) than in group 3 (16%) (P1 versus 3 = 0.04). Of note, topical steroids were only used in group 1 at enrollment (see Table 3 ). At the last follow up, group 1 (25%) still used more steroids than group 2 (20%) and group 3 (5%) (p = 0.03). Also, topical steroids were used more often at follow up in group 1 (12%) than in group 2 (2%) and group 3 (5%) (p = 0.01). Over the entire study period, the use of topical (group 1: 26%, group 2: 13%, group 3: 5%, p = 0.01) and systemic (group 1: 73%, group 2: 72%, group 3: 55%, P1 versus 3 = 0.05) steroids decreased with increasing distance from the tertiary referral centers. The application of 5-ASA, antibiotics, immunomodulators, anti-TNF agents, or other biologicals, as well as calcineurin inhibitors, was not different between groups and did not change over time. The frequency of surgery was not different between groups.
Discussion
To optimize therapy of IBD, patients need access to specialized care and close monitoring of therapy and development of complications, as well as periodical endoscopies. Distance and travel time could negatively influence the implementation of these measures and affect disease outcome.
In this multicenter cohort study of Swiss IBD patients, a shorter distance to an IBD specialist was related to increased use of 5-ASA and anti-TNF agents in CD, as well as an increased use of, particularly, topical steroids in UC patients. In CD, diagnostic delay was shortest in patients living at a larger distance to the specialist. The incidence of a more severe disease course, as represented by the number of surgical interventions, was not related to a longer PTSD, either in CD or in UC/IBDU.
Many studies have shown that an early initiation of medical treatment results in a better outcome in IBD patients. 5, 16, 17 Due to unspecific or mild early symptoms, diagnosing IBD can be demanding. Minimizing the diagnostic delay is, besides early immunomodulator/biological therapy, an important parameter in avoiding complications and surgery. 16, 18, 19 To the best of our knowledge, the influence of distance to center on diagnostic delay has not yet been investigated. Vavricka and colleagues showed that patients from the Swiss IBD Cohort Study are diagnosed with a delay of 9 months in CD and 4 months in UC. 20 In our study, the diagnostic delay was even shorter than previously reported, 20 and we have seen a surprisingly low diagnostic delay of only 2 months in CD patients living over 35 km away from a tertiary IBD center. This observation might indicate a decreasing diagnostic delay within the last years, or also be related to the different sample size out of the same SIBDCS database in this study (408 IBD patients) compared with the above-mentioned Swiss study (1591 IBD patients).
Early treatment with immunomodulators has proven to reduce the risk of intestinal surgery, perianal surgery, and other complications. 21 Other studies suggest that therapies with anti-TNF antibodies even appear to influence fistula healing in CD in a positive manner. 17, 22 The timing of such therapy is of great importance. 23 Another Swiss study showed that treatment with anti-TNF agents started within the first 2 years after diagnosis reduces the risk of developing intestinal strictures in CD. 21 In our study, the use of anti-TNF and immunomodulators at enrollment did not differ between PTSD groups, which could explain the nonexistent difference in occurrence of CD-related complications and perianal fistulizing disease.
Our results are in contrast to a single-center study from Massachusetts that investigated the influence of distance between IBD patients and the Massachusetts General Hospital in Boston on disease outcome. 13 They found an increased need for IBD-related surgery, biologicals, and immunomodulators in patients living at the largest distance from the specialist. Differences between the two studies might be related to different distances to the specialist. Our largest mean distance to specialist was 48.7 km, while it was 81.8 km in Massachusetts. It might be possible that our largest distance was not large enough to detect a difference in treatment and outcome. This is also supported by a study investigating the relationship between distance and outcome after cardiac operations. 24 The outcome was significantly worse in patients living beyond 100 km from the hospital, which is a much larger distance than analyzed in our study.
On the other hand, it has been demonstrated that biological therapy is more often prescribed at specialized centers. 25 From our database, we were not able to determine whether patients were treated at a private practice or in an outpatient setting at the tertiary center. When the cohort study was initiated, it first began recruiting patients at the centers, and later in the periphery. It therefore might be possible that patients living closest to the specialist were actually treated at a center, while the patients living at larger distances were treated at private practices. This might explain our finding that more patients living closest to the specialist were treated with anti-TNF agents (over 70% in group 1 were treated with anti-TNF agents), if analyzing the medication received during the entire study period. This might also apply to our finding that more systemic steroids were used in patients living closest to the specialist in UC/IBDU. Corticosteroids are usually used when therapy with 5-ASA is insufficient, 26, 27 or for treatment of an acute moderateto-severe flare. 27,28 Since we did not detect differences in disease outcome, it is likely that treatment differences between distance groups can be explained by the setting (private practice versus center) in which patients were treated. Telemedicine approaches might be an option to improve treatment outcomes for patients living at longer distances to the specialist.
Increasing disease duration in CD is, besides the above-mentioned delay in immunomodulator/ biological therapy and increased diagnostic delay, a risk factor for repetitive CD-related intestinal surgery and complications. 16 We found a higher median disease duration in patients living closest to the specialist. The cumulative probability for intestinal surgery 10 years after diagnosis is 38% in CD and 25% in UC, respectively. 8, 29 In addition, previous studies found that specialized gastroenterologist in-hospital care results in lower in-hospital mortality risk, 6, 30, 31 and in earlier surgical treatment. 25 However, although we expected a worse disease outcome with increasing PTSD, we did not detect a difference in the occurrence of surgical interventions between groups.
Our study bears several limitations. We excluded the majority of patients from the analysis, as they were enrolled into the cohort later than 6 months after the first presentation to a gastroenterologist. In contrast to the study from Boston, 13 which was monocentric, we had to find a way to ensure stable distances, that is, a stable address, between patients and IBD center from our cohort data, as address data might not have been constantly updated in the database. Compared with the study from Boston, we also had a lower difference between the distance groups: Groups 1 and 3 differed by 25 km. Given the fact, that the IBD centers were 70-100 km apart, we had to choose the distance groups accordingly. However, the rather small difference between the groups might have hampered the identification of more distinct differences. In addition, in the statistical analysis, we were not able to adjust for confounding factors, such as treatment duration (i.e. time on therapy, or if a therapy had to be stopped because of intolerance), socioeconomic status or insurance type, as this was not recorded in the database. These factors might have influenced treatment decisions.
Conclusion
In conclusion, our study shows that, although differences in treatment with PTSD exist, this does not seem to influence the diagnostic delay and disease outcome. This might be related to the small area, and therefore overall short distances, in Switzerland. We had hypothesized that an increase in distance between patient's home and IBD specialist might have an adverse impact on diagnosis and disease outcome. While we detected a difference in treatment, disease complications did not differ.
